Sie sind auf Seite 1von 9

From bloodjournal.hematologylibrary.org by guest on October 21, 2013. For personal use only.

2013 122: 2310-2317 Prepublished online July 10, 2013; doi:10.1182/blood-2013-04-460162

Treatment of cancer-associated thrombosis


Agnes Y. Y. Lee and Erica A. Peterson

Updated information and services can be found at: http://bloodjournal.hematologylibrary.org/content/122/14/2310.full.html Articles on similar topics can be found in the following Blood collections Free Research Articles (1974 articles) Multiple Myeloma (179 articles) Review Articles (474 articles) Review Series (13 articles) Thrombosis and Hemostasis (624 articles) Information about reproducing this article in parts or in its entirety may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests Information about ordering reprints may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints Information about subscriptions and ASH membership may be found online at: http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml

Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036. Copyright 2011 by The American Society of Hematology; all rights reserved.

Review Series
CANCER-ASSOCIATED THROMBOTIC DISEASE

Treatment of cancer-associated thrombosis


Agnes Y. Y. Lee and Erica A. Peterson
Division of Hematology, Department of Medicine, University of British Columbia, British Columbia Cancer Agency, Vancouver, BC, Canada

Therapeutic options for the management of venous thromboembolism (VTE) in patients with cancer remain very limited. Although low-molecular-weight heparin monotherapy has been identified as a simple and efficacious regimen compared with an initial parenteral anticoagulant followed by long-term therapy with a vitamin K antagonist, many clinical questions remain unanswered. These include optimal duration of anticoagulant therapy, treatment

of recurrent VTE, and the treatment of patients with concurrent bleeding or those with a high risk of bleeding. Treatment recommendations from consensus clinical guidelines are largely based on retrospective reports or extrapolated data from the noncancer population with VTE, as randomized controlled trials focused on cancer-associated thrombosis are sorely lacking. Furthermore, with improvements in imaging technology and extended

survival duration of patients with cancer, we are encountering more unique challenges, such as the management of incidental VTE. Clinicians should be aware of the limitations of the novel oral anticoagulants and avoid the use of these agents because of the paucity of evidence in the treatment of cancer-associated thrombosis. (Blood. 2013;122(14):23102317)

Introduction
Venous thromboembolism (VTE) is a signicant cause of morbidity and mortality in patients with cancer.1 Although deep vein thrombosis (DVT) and pulmonary embolism (PE) are the most commonly encountered venous thrombotic complications, other vascular territories, such as the splanchnic veins and upper extremity venous system, can also be involved. With the increasing age and cancer prevalence of our population, enhanced detection of incidental thrombosis and greater thrombogenicity of multiagent chemotherapeutic regimens, we have observed a steady increase in the incidence of cancer-associated thrombosis during the past 2 decades.2,3 A leading cause of death in patients with cancer,4 thrombosis is associated with higher mortality risk, irrespective of cancer stage.5,6 Unfortunately, despite the burden of VTE in oncology patients, there has been limited advancement in the management of cancerassociated thrombosis since the introduction of low-molecularweight heparin (LMWH) for long-term therapy. Anticoagulant therapy in malignancy remains burdensome and is viewed as having a negative impact on patient quality of life. It is also associated with a high risk of bleeding and may limit the therapeutic options to treat the underlying cancer.7 In this review, we outline the current evidence and consensus guideline recommendations for the initial and long-term management of the rst and recurrent episodes of VTE in patients with cancer. We also discuss the management of commonly encountered thrombotic complications, recognizing the lack of rigorous evidence in these areas, such as incidentally detected VTE, splanchnic vein thrombosis, catheter-related thrombosis, and VTE treatment in patients with a high risk of bleeding. We close with a critical look at the use of the novel oral anticoagulants (NOACs) in the treatment of cancer-associated thrombosis.

Initial management of a first episode of cancer-associated VTE


Choice of anticoagulant

Options for the initial treatment of cancer-associated thrombosis include LMWH, unfractionated heparin (UFH), and fondaparinux. Although studies directly comparing these agents are lacking in oncology patients, data extrapolated from subgroup analysis of trials in unselected patients showed no difference in efcacy between LMWH and UFH in patients with cancer.8 However, a statistically signicant reduction in mortality risk with LMWH at 3 months of follow-up has been noted. The reason for this survival benet is unknown, but research exploring the antineoplastic properties of LMWH is ongoing. In addition to better efcacy, LMWH provides other advantages vs UFH, including lower cost (because hospitalization and laboratory monitoring are not required) and simple dosing (because the total daily dose is based on body weight). LMWH is also associated with a lower risk for heparin-induced thrombocytopenia (HIT).9 Data on the use of fondaparinux for the initial management of DVT and PE in patients with cancer are also derived from post hoc subgroup analysis. In the Matisse trials, the 3-month rate for symptomatic, recurrent VTE was higher for fondaparinux vs enoxaparin in DVT treatment (12.7% vs 5.4%) but was lower for fondaparinux vs UFH in PE treatment (8.9% vs 17.2%).10 Like LMWH, fondaparinux is administered as a once-daily, weight-based subcutaneous injection. Fondaparinux is rarely associated with the development of

Submitted April 3, 2013; accepted June 20, 2013. Prepublished online as Blood First Edition paper, July 10, 2013; DOI 10.1182/blood-2013-04-460162.

2013 by The American Society of Hematology

2310

BLOOD, 3 OCTOBER 2013 x VOLUME 122, NUMBER 14

BLOOD, 3 OCTOBER 2013 x VOLUME 122, NUMBER 14

TREATMENT OF CANCER-ASSOCIATED THROMBOSIS

2311

Table 1. Consensus guidelines on treatment of deep vein thrombosis or pulmonary embolism in patients with cancer
ACCP 201221 Initial/acute treatment Not addressed in cancer patients. LMWH Dalteparin 200 U/kg OD Enoxaparin 1 mg/kg BID Tinzaparin 175 U/kg OD Fondaparinux 5 mg (,50 kg), 7.5 mg (50-100 kg), or 10 mg (.100 kg) OD APTT-adjusted UFH infusion Long-term treatment In patients not treated with LMWH, VKA therapy is preferred to dabigatran or rivaroxaban [2C].* Patients receiving extended therapy should continue with the same agent used for the first 3 mo of treatment [2C].* Duration of treatment Extended anticoagulant therapy is preferred to 3 mo of treatment [2B].* Minimum 3 mo. Indefinite anticoagulant if active cancer or persistent risk factors. At least 6 mo duration. Extended anticoagulation with LMWH or VKA may be considered beyond 6 mo for patients with metastatic disease or patients who are receiving chemotherapy. ACCP, American College of Chest Physicians; BID, twice-daily dosing; NCCN, National Comprehensive Cancer Network; OD, once-daily dosing. *ACCP adaptation of the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) Working Group evidence-based recommendations: 2B, weak recommendation, moderate-quality evidence; 2C, weak recommendation, low- or very-low-quality evidence.16 LMWH preferred to VKA [2B].* LMWH is preferred for first 6 mo as monotherapy without warfarin in patients with proximal DVT or PE and metastatic or advanced cancer. Warfarin 2.5-5 mg every day initially with subsequent dosing based on INR value targeted at 2-3. VKAs (target INR, 2-3) are acceptable for long-term therapy if LMWH is not available. LMWH is preferred for long-term therapy. NCCN 201113 ASCO 201314 LMWH is preferred for initial 5-10 d of treatment in patients with a CrCl .30 mL/min.

drug-induced thrombocytopenia and has been used off label for the management of HIT.11 Barriers to its use in oncology patients include a relatively long half-life of 17 to 21 hours, the lack of a reversal agent, and 100% dependence on renal clearance.12 On the basis of currently available evidence, LMWH is the recommended anticoagulant for the initial therapy of VTE in most patients with cancer (Table 1).13-16 However, UFH can be used in those with severe renal impairment (creatinine clearance [CrCl] ,30 mL/min) given its shorter half-life, reversibility with protamine sulfate, and dependence on hepatic clearance. Fondaparinux is a reasonable choice in patients with a history of HIT.
Use of thrombolysis in cancer-associated VTE

As most trials of thrombolytic therapy exclude patients with cancer because of a perceived higher risk of bleeding, evidence for thrombolysis in patients with malignancy is limited to small single-center, retrospective series. These studies compared the degree of clot lysis and short-term complications between patients with vs those without cancer who had presented with extensive DVT or PE.17-19 Although comparable results between cancer and noncancer patient groups were observed, these studies provide a low level of evidence because of insufcient statistical power and patient selection bias. Nonetheless, there is no strong evidence to routinely exclude patients for consideration of thrombolysis on the basis of the presence of malignancy alone. Because the safety, cost-effectiveness, and longterm benet of thrombolysis remain uncertain,20 it is prudent to review each patient carefully and exclude patients with central nervous system lesions or other risk factors for bleeding.

Long-term management of a first episode of cancer-associated VTE


Choice of anticoagulant

acute VTE in patients without cancer,21 their use is problematic in oncology patients. VKAs are less effective in patients with cancer, with rates of recurrent VTE threefold higher than in patients without cancer despite maintenance of the international normalized ratio (INR) within the therapeutic range.22,23 Several open-label, randomized controlled trials have compared LMWH with VKA therapy for long-term management of cancerassociated PE or proximal DVT (Figure 1).24-27 Three different LMWH preparations, enoxaparin, tinzaparin, and dalteparin, were investigated for 3 to 6 months in similarly designed studies. Overall, the results from these trials provide consistent evidence of improved efcacy of LMWH vs VKA in the prevention of recurrent VTE in patients with cancer-associated VTE. A meta-analysis of 7 studies conrms this nding, reporting a relative risk reduction of 53%.28 In addition to improved efcacy vs VKA therapy, LMWH also offers other advantages including (a) no need for laboratory monitoring of its anticoagulant activity; (b) a shorter half-life that facilitates temporary interruption for procedures or thrombocytopenia; (c) limited drug interactions; and (d) no food interactions or reliance on oral intake or gastrointestinal tract absorption. As a result, LMWH is recommended for both initial and long-term anticoagulation in cancer-associated thrombosis by major consensus guidelines (Table 1).13-15,21 The high cost associated with LMWH therapy and the requirement for daily subcutaneous injections are the major barriers to its use. Yet, qualitative studies have reported that patient acceptance of daily injections is quite favorable.29 In fact, in those who had used warfarin and LMWH therapy, most prefer the convenience and empowerment with LMWH. If LMWH is unavailable, the American Society of Clinical Oncology (ASCO) 2013 VTE Prevention and Treatment Guideline recommends the use of VKA with a target INR of 2 to 3 as an acceptable alternative.14
Anticoagulation in patients with renal impairment

Although vitamin K antagonists (VKAs) have been the mainstay agents for long-term management and secondary prophylaxis of

Renal impairment is not uncommon among patients with malignancy. Because LMWH is partially cleared by renal excretion and metabolism, drug accumulation is expected with long-term use in

2312

LEE and PETERSON

BLOOD, 3 OCTOBER 2013 x VOLUME 122, NUMBER 14

renal impairment has been issued by the US Food and Drug Administration after the results of an interim analysis of a randomized trial comparing tinzaparin with UFH for initial VTE therapy in this vulnerable population.35 Only 33 patients with a history of ongoing malignancy were enrolled in this study; 20 of them were in the tinzaparin group.36
Duration of anticoagulation and anticoagulant options for extended therapy

Figure 1. Comparison of randomized controlled trials of different preparations of LMWH vs VKA for the long-term management of cancer-associated thrombosis. Recurrent VTE (A), major bleeding episodes (B), and mortality (C) during the anticoagulant treatment period are shown for the CLOT24 (6 months of dalteparin or VKA), LITE25 (3 months of tinzaparin or warfarin), and CANTHANOX27 (3 months of enoxaparin or warfarin) trials. NS, not statistically significant.

The decision regarding the continuation of anticoagulation beyond the rst 3 to 6 months is largely based on weighing the risk for recurrent thrombosis against the risk of major bleeding. This evaluative process is best developed in patients with unprovoked VTE, in whom studies have been done to determine whether biomarkers, radiologic imaging, and clinical prediction models can identify patients with a sufciently high risk for recurrent thrombosis to benet from extended anticoagulation, or an acceptably low risk to allow discontinuation of anticoagulation.37-39 A clinical model to predict the risk for recurrent VTE during anticoagulation therapy in cancer-associated thrombosis has been proposed but not yet validated.40 In addition, studies regarding the optimal duration of anticoagulant therapy are lacking in oncology patients. Given that the risk for recurrent thrombosis in patients with active cancer is high even while they are receiving anticoagulation, it is generally recommended that extended anticoagulation be considered in this population.14,21 It has not been established whether risk factors for a rst episode of VTE, such as metastatic or progressive disease and ongoing chemotherapy, will also increase the risk for recurrent VTE, but it has been generally accepted that continuing anticoagulation in patients with these ongoing risk factors is warranted.13-15 Patients given extended anticoagulation require frequent reassessment to review the risk-benet balance of continuing anticoagulant therapy. Factors that need to be taken into account, aside from the risk for recurrent VTE and the risk of bleeding, include the status of the malignancy, type of cancer treatment (if any), quality of life, and patient preference. The choice of anticoagulant for extended anticoagulant therapy (beyond 6 months) also has not been investigated. A randomized trial is currently addressing this question.41 Patient preference and tolerance of previous therapy play signicant roles in this decision. Thus far, long-term toxicity associated with VKA or LMWH has not been a concern, although it remains controversial whether prolonged exposure to LMWH accelerates clinically signicant bone loss.42 As with duration of therapy, the anticoagulant of choice needs to be discussed with each patient and individualized.
Inferior vena cava (IVC) filters

those with signicant renal insufciency (CrCl ,30 mL/min). Of the major LMWH preparations, tinzaparin appears to have the lowest potential to accumulate, whereas enoxaparin shows signicant accumulation in renal insufciency.30 This property reects the chain length of the LMWH, with the longer-chain tinzaparin being partially cleared by the reticuloendothelial system.30,31 Limited data are available on the use of LMWH in patients with signicant renal dysfunction, but they do indicate that the risk of bleeding is higher in patients with renal impairment.32,33 Manufacturer-recommended dose reduction in renal impairment exists for enoxaparin but not for other LMWH preparations.34 Most experts and guidelines recommend dose adjustment based on anti-factor Xa activity in patients with a CrCl ,30 mL/min.13,21 If anti-factor Xa monitoring is not readily available, VKA therapy is likely a safer option for long-term anticoagulation in these patients. A warning against the use of tinzaparin in elderly patients with

Patients with cancer are frequent recipients of IVC lters. Yet, data on the efcacy and safety in this population are limited to retrospective single-center series or anecdotal reports.43,44 Rates of recurrent VTE up to 32% have been reported in patients with cancer treated with IVC lters, and fatal PE after lter insertion has been well documented.45 Evidence on the safety and efcacy of IVC lters in the general population is also sparse. Only 1 randomized trial has been done to evaluate lter placement in patients with proximal DVT who are at high risk for PE. In the PREPIC (Pr evention du Risque dEmbolie Pulmonaire par Interruption Cave) trial, the use of permanent IVC lters in conjunction with anticoagulation resulted in a decreased incidence of PE at the expense of an increase risk for recurrent DVT and without any reduction in overall mortality rate during 8 years of follow-up.46,47 Results for the included 56 patients with cancer

BLOOD, 3 OCTOBER 2013 x VOLUME 122, NUMBER 14

TREATMENT OF CANCER-ASSOCIATED THROMBOSIS

2313

have not been published. Most importantly, the value of an IVC lter in patients who cannot receive anticoagulation, the major indication for lter insertion, has not been examined in prospective studies. Complications associated with IVC lters raise further concern about the appropriateness of their use. Insertion problems occur in 4% to 11% of patients, and long-term adverse effects such as thrombosis of the IVC or lower extremity veins occur in 4% to 32%.48 A high incidence of mechanical or device failures associated with retrievable lter models led the US Food and Drug Administration to issue a Safety Alert in 2010.49 These problems include lter migration, strut fracture with embolization, and caval perforation.50,51 Given the high rates of complications and the absence of data to support their efcacy, IVC lters should be restricted to patients with acute VTE and contraindications to anticoagulation. Their use in patients with recurrent thrombotic events despite standard anticoagulant therapy goes against biological rationale because lters do not treat the underlying thrombotic condition, and the presence of an intravascular foreign body is likely to promote thrombus formation, which can occur proximally or distally to the lter. In addition, the use of IVC lters may provide a sense of false security regarding the risk for recurrent PE, causing delays or discontinuation of anticoagulant therapy. If retrievable lters are placed, efforts should be made to remove the device and reinitiate anticoagulation as soon as the high-risk period for bleeding has passed.

Treatment of recurrent VTE during anticoagulant therapy


Failure of anticoagulation in cancer-associated thrombosis is common, but there is a paucity of data to help guide treatment. An empiric approach for the treatment of recurrent VTE during anticoagulant therapy is outlined in Figure 2. Once recurrent VTE is conrmed, it is essential that HIT be excluded in patients who were rst exposed to LMWH or UFH within the past 10 to 14 days. Compliance should also be reviewed. In patients who experience a recurrent event while receiving VKA therapy and have a subtherapeutic INR, options include continuation of VKA after a bridging period with LMWH (or UFH) or switching to LMWH monotherapy. The latter is likely a better option, especially in patients who had unstable INR values and the time-in-therapeutic range was low. For patients who experienced warfarin failure while the INR values had been therapeutic, transition to LMWH is recommended given its greater efcacy vs warfarin.24,25,27,52 Recurrent VTE events during LMWH therapy can be treated with a dose escalation of LMWH. A retrospective study of 70 patients with cancer with recurrent VTE demonstrated that transition to LMWH (in patients receiving VKA therapy at the time of recurrence) or LMWH dose escalation by 20% to 25% (in patients receiving LMWH at recurrence) prevented additional VTE in 91% of patients during a minimum of 3 months of follow-up.53 Only 1 patient had a major bleeding event. If another recurrent VTE episode occurs after the rst dose escalation, further dose increase or twice-daily dosing of LMWH are reasonable options. The use of anti-factor Xa levels may help to further tailor LMWH escalation (Figure 2), although published evidence to support this strategy is lacking.

Figure 2. Management algorithm of recurrent VTE in patients with cancer. BID, twice-daily dosing; INR, international normalized ratio; OD, once-daily dosing.

Treatment of incidental VTE


Incidental or unsuspected VTE is dened as evidence of thrombosis detected on imaging studies performed for other indications such

as cancer staging.54 Retrospective studies in unselected oncology patients have demonstrated incidental VTE rates of up to 6%,55,56 with thrombotic events evenly distributed between PE and/or DVT and intra-abdominal thrombosis.55 A prevalence of incidental PE of 3.1% was reported in a meta-analysis that included data from more than 6000 oncology patients.57 Incidental VTE also represents a signicant proportion of thrombotic complications in patients with cancer, comprising up to 60% in large series.58 Studies have suggested that, like suspected or symptomatic VTE, the occurrence of incidental VTE can have a negative impact on both patient quality of life and clinical outcomes. Patients with incidental PE often have symptoms such as fatigue and shortness of breath.59 In a retrospective case-control study comparing 51 unselected oncology patients with incidental PE and 144 patients with symptomatic PE, the 12-month rates of recurrent VTE, bleeding, and mortality were similar between the groups.60 A retrospective cohort of 135 consecutive patients with pancreatic cancer reported similar ndings.61 In another study, a comparison of cancer patients with and without incidental PE matched for age, cancer diagnosis, and stage of disease at the time of a restaging computed tomography scan of the chest found that patients with incidental PE had a higher mortality rate than those without PE.62 Whether anticoagulation is indicated or benecial in patients with incidental VTE remains controversial. Evidence is limited to 2 retrospective studies in patients with lung and pancreatic cancer. In a cohort of 113 patients with lung cancer and incidental PE, the 62 patients who did not receive anticoagulation had higher mortality

2314

LEE and PETERSON

BLOOD, 3 OCTOBER 2013 x VOLUME 122, NUMBER 14

rates compared with patients who were treated.63 Similarly, in patients with pancreatic cancer with incidental VTE, the use of anticoagulant therapy was associated with a 70% reduction in mortality rate.61 However, these studies are potentially biased to favor anticoagulation because anticoagulant therapy is likely to be withheld in those with a short life expectancy. Nonetheless, based on published literature to date, it is recommended that patients with incidental DVT and PE receive therapeutic anticoagulation if there are no contraindications.14,21 However, caution should be exercised in cases where the diagnosis of PE or DVT is questionable, especially for isolated subsegmental PE. Conrming the diagnosis with the appropriate testing (ie, computed tomographic pulmonary angiography or compression venous ultrasonography) is strongly encouraged in such cases.

Treatment of cancer-associated thrombosis in patients with a high risk of bleeding


Bleeding is frequently associated with anticoagulant use in patients with cancer. In a prospective study including 181 oncology patients receiving VKA for the treatment of DVT, the 1-year cumulative incidence of major bleeding was 12.4%, with one third of the bleeding events occurring during the initial phase of anticoagulation.23 Although subtherapeutic INR values are associated with recurrent VTE, there appears to be no correlation between the INR level and bleeding in patients with cancer.22,64 Bleeding complications are not restricted to VKA therapy, as prospective randomized controlled trials comparing LMWH and VKA therapy for cancerassociated VTE have reported similar bleeding rates.24-26 Features specic to oncology patients that contribute to bleeding include the extent, location, and histologic features of the cancer, need for invasive diagnostic or treatment procedures, and the development of thrombocytopenia from chemotherapy or from the underlying malignancy. Other comorbidities such as renal impairment and coagulopathy from liver dysfunction, disseminated intravascular coagulopathy, or sepsis further predispose them to bleeding. Because of potentially serious and life-threatening bleeding complications, all patients require an individualized assessment of their bleeding risk before the initiation of anticoagulation. Current and potential bleeding sources should be identied and managed, and the risk of serious bleeding should be weighed against the severity of the thrombotic event and risk for recurrent VTE. In patients with minor bleeding, anticoagulation may be continued as long as close follow-up is available. In patients with absolute contraindications to anticoagulation, the risk of bleeding likely outweighs the benet of treatment, and anticoagulants should be withheld.14 In these patients, follow-up imaging should be performed to assess for thrombus progression, and IVC lter insertion can be considered. If severe cancer- or chemotherapy-induced thrombocytopenia is present, platelet transfusions may be used to allow anticoagulation. Most experts agree that therapeutic anticoagulation with LMWH may be administered if the platelet count can be maintained above 50 3 109/L.65 For platelet counts between 20 and 50 3 109/L, half-dose LMWH can be administered with close follow-up for possible bleeding. If platelet count is ,20 3 109/L, therapeutic doses of anticoagulation should be held. Limited evidence from case series suggests that the use of prophylactic doses of LMWH can be tolerated in patients with platelet counts ,20 3 109/L with associated resolution of thrombotic symptoms.66 VKA therapy should be avoided in patients with severe thrombocytopenia from

Figure 3. Management algorithm of VTE in patients with cancer and thrombocytopenia. Management of acute VTE (,1 month) and subacute or chronic VTE ($1 month) are outlined in panels A and B, respectively.

the prolonged anticoagulant effect and unpredictable dose response. Figure 3 illustrates a reasonable approach to the treatment of cancerassociated thrombosis in patients with thrombocytopenia.65 Management of VTE in patients with intracranial malignancies is particularly challenging because of the fear of intracranial hemorrhage. No randomized controlled data exist for management of patients with primary or metastatic intracranial tumors and VTE; however, small retrospective studies indicate that anticoagulation can be safely used. Anticoagulation with intravenous UFH followed by VKA or subcutaneous UFH has been associated with rates of symptomatic intracranial hemorrhage between 0% and 7%.67-70 Similar results have been reported with LMWH in patients with glioma or metastatic brain tumors with a trend toward improved survival duration.71-73 The ASCO 2013 VTE Guideline recommends treating patients with intracranial malignancies with standard anticoagulation.14

Treatment of catheter-related thrombosis


Treatment of catheter-related thrombosis is largely inferred from treatment of DVT because randomized controlled trials evaluating management strategies have not been performed. Whether line removal is necessary (to eliminate the thrombotic source), harmful (because it can trigger PE), or benecial (in shortening or avoiding anticoagulation therapy) has not been studied in clinical trials. A small prospective study evaluating the use of anticoagulation alone reported that in 74 patients with active cancer, LMWH for 5 to 7 days followed by warfarin with a target INR of 2.0 to 3.0 for 3 months resulted in no recurrent VTE at the expense of 3 episodes of major bleeding, including 1 fatal hemorrhage.74 After 3 months of treatment, 57% of patients had functional catheters in situ, whereas the remainder had catheter removal for reasons other than progressive thrombosis or device failure. A small patient series observed that a

BLOOD, 3 OCTOBER 2013 x VOLUME 122, NUMBER 14

TREATMENT OF CANCER-ASSOCIATED THROMBOSIS

2315

Table 2. Interactions between chemotherapeutic agents and immunosuppressants with NOACs based on known metabolic pathway activity
Dabigatran Interaction effect* Increases NOAC plasma levels P-glycoprotein Cyclosporine Tacrolimus Tamoxifen Lapatinib Nilotinib Sunitinib Reduces NOAC plasma levels Dexamethasone Doxorubicin Vinblastine Rivaroxaban P-glycoprotein CYP3A4 Cyclosporine Tacrolimus Tamoxifen Lapatinib Nilotinib Sunitinib Imatinib Dexamethasone Doxorubicin Vinblastine Apixaban P-glycoprotein CYP3A4 Cyclosporine Tacrolimus Tamoxifen Lapatinib Nilotinib Sunitinib Imatinib Dexamethasone Doxorubicin Vinblastine

the use of anticoagulant therapy.21 For patients with incidentally detected splanchnic vein thrombosis, there is no specic guidance on treatment. It is reasonable to withhold anticoagulation if the patient is truly asymptomatic, especially if radiologic evidence indicates that the thrombus is chronic in nature. Repeated imaging is prudent to detect thrombus progression if anticoagulation is not given.

Use of NOACs in cancer-associated thrombosis


The development of NOACs that directly inhibit factor Xa or thrombin is a milestone achievement in the prevention and treatment of VTE. These agents are more attractive to patients and clinicians because they are taken by mouth in xed doses once or twice daily, have few drug and food interactions, and do not require laboratory monitoring. Dabigatran, a direct thrombin inhibitor, and rivaroxaban and apixaban, 2 direct factor Xa inhibitors, are the forerunners in this class of agents. These drugs have been shown to be effective in VTE prophylaxis after major hip and knee arthroplasty and in stroke prevention in patients with nonvalvular atrial brillation.81 They are also noninferior to warfarin for the prevention of recurrent VTE without an increased risk of bleeding, and rivaroxaban has received regulatory approval as monotherapy in the treatment of DVT.82-87 All 3 agents are effective and safe for long-term secondary VTE prophylaxis in patients who have already received 6 to 12 months of anticoagulation.82,85,87 Unfortunately, very small numbers of patients with cancer were included in these trials, and the results of this patient subgroup have not been published. A small phase 2 study evaluating the safety and tolerability of apixaban found a low risk of major bleeding (2.2%) during 12 weeks of therapy in 125 patients with metastatic or advanced cancer without thrombosis.88 No studies have specically addressed the treatment of cancer-associated VTE using these direct inhibitors. Despite the undeniable practical advantages of these agents vs VKA and LMWH therapy for the prevention and treatment of cancerassociated thrombosis, important and clinically relevant concerns prevail regarding the extrapolation of published results to the cancer population. These include the small number of highly selected patients with cancer (approximately 5%) enrolled in each study and the use of warfarin or placebo rather than LMWH in the control group. In addition, although these anticoagulants have fewer drug interactions than VKAs, interactions do exist with some chemotherapeutic agents (Table 2). Whether these interactions are clinically signicant is not known. Finally, gastrointestinal tract problems in patients with cancer can potentially alter drug delivery and absorption, and higher rates of gastrointestinal tract bleeding have been reported with dabigatran compared with warfarin.81 These shortcomings are compounded by the lack of reversal agents to rapidly normalize hemostasis and the lack of widely available laboratory assays to measure the anticoagulant activity. Clinicians need to discuss these limitations to fully inform their patients with cancer and know that the current ASCO Guideline does not recommend the use of these new agents.14 Clinical trials are strongly encouraged to address this and the many other unmet clinical needs in patients with cancerassociated thrombosis.

CYP3A4, cytochrome P450 3A4. *Clinicians should consult with the pharmacist to determine if these and other drug interactions exist when NOACs are being considered. Drugs that inhibit P-glycoprotein transport or CYP3A4 pathway can increase NOAC levels. Drugs that induce P-glycoprotein transport or CYP3A4 pathway can lower NOAC levels.

short course of low-dose LMWH is effective and safe in treating catheter-related thrombosis in patients with severe thrombocytopenia.75 To date, published data and clinical experience suggest that catheter-related thrombosis is associated with a low risk for thrombosis recurrence and postthrombotic syndrome.76,77 Therefore, conservative treatment is recommended. A sensible approach is to remove the catheter only if (1) central venous access is no longer required; (2) the device is nonfunctional or defective; or (3) line-related sepsis is suspected or documented. Unless contraindicated, therapeutic anticoagulation should be given using either LMWH alone or LMWH followed by warfarin therapy. A short period of anticoagulation (3-5 days of LMWH) may even salvage some thrombosed catheters and obviate the need to remove and replace the line. Anticoagulation is recommended for a minimum of 3 months and while the catheter remains in place.

Treatment of splanchnic vein thrombosis in patients with cancer


Splanchnic vein thromboses, involving the portal, splenic, mesenteric, or hepatic veins, are uncommon in the general population, but signicant rates have been reported in patients with intraabdominal malignancies.78 In a retrospective single-institution study of 135 consecutive patients with pancreatic adenocarcinoma, incidental splanchnic vein thrombosis was present in 23%.60 Management of splanchnic vein thrombosis has not been well studied. Limited experience is available from studies that included both patients with and without cancer. In a retrospective cohort of 832 patients with splanchnic vein thrombosis, of which 27% had underlying cancer, warfarin therapy and gastrointestinal tract varices were independent predictors of bleeding.79 Furthermore, VTE recurrence was not reduced after anticoagulant therapy. An international registry of 613 patients with splanchnic vein thrombosis reported that most patients are treated with anticoagulation and that the risk of major bleeding is low.80 Whether such results apply to cancer-related splanchnic vein thrombosis is not known. In patients with acute, symptomatic splanchnic vein thrombosis without contraindications to anticoagulation, guidelines recommend

Authorship
Contribution: A.Y.Y.L. and E.A.P. wrote the manuscript.

2316

LEE and PETERSON

BLOOD, 3 OCTOBER 2013 x VOLUME 122, NUMBER 14

Conict-of-interest disclosure: A.Y.Y.L. reports receiving research funding from LEO Pharma and honoraria from Bayer, BoehringerIngelheim, Bristol-Myers Squibb, LEO Pharma, Pzer, and Sano Aventis. The remaining author declares no competing nancial interests.

Correspondence: Agnes Y. Y. Lee, University of British Columbia and Vancouver Coastal Health Diamond Health Care Centre, 2775 Laurel St, 10th Floor, Vancouver, BC, Canada; email: alee14@ bccancer.bc.ca.

References
1. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107(23 Suppl 1):I17-I21. 2. Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006;24(3):484-490. 3. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006;119(1):60-68. 4. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632-634. 5. Chew HK, Wun T, Harvey DJ, Zhou H, White RH. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol. 2007;25(1):70-76. 6. Rodriguez AO, Wun T, Chew H, Zhou H, Harvey D, White RH. Venous thromboembolism in ovarian cancer. Gynecol Oncol. 2007;105(3): 784-790. 7. Kuderer NM, Ortel TL, Francis CW. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol. 2009; 27(29):4902-4911. 8. Akl EA, Vasireddi SR, Gunukula S, et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2011;(6): CD006649. 9. Martel N, Lee J, Wells PS. Risk for heparininduced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106(8):2710-2715. 10. van Doormaal FF, Raskob GE, Davidson BL, et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost. 2009; 101(4):762-769. 11. Warkentin TE, Pai M, Sheppard JI, Schulman S, Spyropoulos AC, Eikelboom JW. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotoninrelease assay: a 30-month, 16-patient case series. J Thromb Haemost. 2011;9(12): 2389-2396. 12. Nagler M, Haslauer M, Wuillemin WA. Fondaparinux - data on efficacy and safety in special situations. Thromb Res. 2012;129(4): 407-417. 13. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology Venous Thromboembolic Disease version 2.2013. Available at: http://www.nccn.org/professionals/ physician_gls/pdf/vte.pdf. Accessed July 9, 2013. 14. Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update. J Clin Oncol. 2013;31(17): 2189-2204. 15. Mandala ` M, Falanga A, Roila F; ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22(Suppl 6):vi85-vi92. 16. Guyatt GH, Norris SL, Schulman S, et al. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):53S-70S. 17. Maleux G, Marchal P, Palmers M, et al. Catheterdirected thrombolytic therapy for thoracic deep vein thrombosis is safe and effective in selected patients with and without cancer. Eur Radiol. 2010;20(9):2293-2300. 18. Kim HS, Preece SR, Black JH, Pham LD, Streiff MB. Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients. J Vasc Surg. 2008;47(2):388-394. 19. Mikkola KM, Patel SR, Parker JA, Grodstein F, Goldhaber SZ. Attenuation over 24 hours of the efficacy of thrombolysis of pulmonary embolism among patients with cancer. Am Heart J. 1997; 134(4):603-607. 20. Vedantham S, Goldhaber SZ, Kahn SR, et al. Rationale and design of the ATTRACT Study: a multicenter randomized trial to evaluate pharmacomechanical catheter-directed thrombolysis for the prevention of postthrombotic syndrome in patients with proximal deep vein thrombosis. Am Heart J. 2013;165(4):523-530.e3. 21. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl): e419S-94S. 22. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000;18(17):3078-3083. 23. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484-3488. 24. Lee AY, Levine MN, Baker RI, et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-153. 25. Hull RD, Pineo GF, Brant RF, et al; LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006; 119(12):1062-1072. 26. Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J; ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 2006;12(4):389-396. 27. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162(15):1729-1735. 28. Akl EA, Labedi N, Barba M, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2011;(6):CD006650. 29. Noble SI, Finlay IG. Is long-term low-molecularweight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat Med. 2005;19(3):197-201. 30. Crowther M, Lim W. Low molecular weight heparin and bleeding in patients with chronic renal failure. Curr Opin Pulm Med. 2007;13(5):409-413. 31. Lim W. Low-molecular-weight heparin in patients with chronic renal insufficiency. Intern Emerg Med. 2008;3(4):319-323. 32. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006;144(9):673-684. 33. Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy. 2001; 21(2):218-234. 34. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother. 2009; 43(6):1064-1083. 35. United States Food and Drug Administration Center for Drug Evaluation and Research. Communication about an Ongoing Safety Review of Innohep (tinzaparin sodium injection). Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsand Providers/DrugSafetyInformationforHeathcare Professionals/ucm136254.htm. Accessed March 23, 2013. 36. Leizorovicz A, Siguret V, Mottier D, et al; Innohep in Renal Insufficiency Study Steering Committee. Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep in Renal Insufficiency Study (IRIS). Thromb Res. 2011;128(1): 27-34. 37. Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121(14):1630-1636. 38. Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost. 2012;10(6):1019-1025. 39. Rodger MA, Kahn SR, Cranney A, et al; TIPPS investigators. Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. J Thromb Haemost. 2007;5(8):1600-1606. 40. Louzada ML, Carrier M, Lazo-Langner A, et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancerassociated venous thromboembolism. Circulation. 2012;126(4):448-454.

BLOOD, 3 OCTOBER 2013 x VOLUME 122, NUMBER 14

TREATMENT OF CANCER-ASSOCIATED THROMBOSIS

2317

41. Kamphuisen PW. Long-term treatment for cancer patients with deep vein thrombosis or pulmonary embolism (LONGEVA). ClinicalTrials.gov Identifier: NCT01164046. Available at: http:// clinicaltrials.gov/ct2/show/NCT01164046? term5LONGHEVA&rank51. Accessed March 23, 2013. 42. Wawrzynska L, Tomkowski WZ, Przedlacki J, Hajduk B, Torbicki A. Changes in bone density during long-term administration of low-molecularweight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb. 2003;33(2):64-67. 43. Wallace MJ, Jean JL, Gupta S, et al. Use of inferior vena caval filters and survival in patients with malignancy. Cancer. 2004;101(8):1902-1907. 44. Schunn C, Schunn GB, Hobbs G, Vona-Davis LC, Waheed U. Inferior vena cava filter placement in late-stage cancer. Vasc Endovascular Surg. 2006;40(4):287-294. 45. Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med. 2004;164(15):1653-1661. 46. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Pr evention du Risque dEmbolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. 1998;338(7):409-415. 47. PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque dEmbolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005;112(3):416-422. 48. Streiff MB. Vena caval filters: a comprehensive review. Blood. 2000;95(12):3669-3677. 49. United States Food and Drug Administration. Removing Retrievable Inferior Vena Cava Filters: Initial Communication. Available at: http://www. fda.gov/MedicalDevices/Safety/AlertsandNotices/ ucm221676.htm. Accessed March 22, 2013. 50. Durack JC, Westphalen AC, Kekulawela S, et al. Perforation of the IVC: rule rather than exception after longer indwelling times for the Gunther Tulip and Celect retrievable filters. Cardiovasc Intervent Radiol. 2012;35(2):299-308. 51. Nicholson W, Nicholson WJ, Tolerico P, et al. Prevalence of fracture and fragment embolization of Bard retrievable vena cava filters and clinical implications including cardiac perforation and tamponade. Arch Intern Med. 2010;170(20): 1827-1831. 52. Luk C, Wells PS, Anderson D, Kovacs MJ. Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med. 2001;111(4):270-273. 53. Carrier M, Le Gal G, Cho R, Tierney S, Rodger M, Lee AY. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost. 2009;7(5):760-765. 54. Khorana AA, OConnell C, Agnelli G, Liebman HA, Lee AY; Subcommittee on Hemostasis and Malignancy of the SSC of the ISTH. Incidental venous thromboembolism in oncology patients. J Thromb Haemost. 2012;10(12):2602-2604. 55. Cronin CG, Lohan DG, Keane M, Roche C, Murphy JM. Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT. AJR Am J Roentgenol. 2007;189(1):162-170. 56. Douma RA, Kok MG, Verberne LM, Kamphuisen uller HR. Incidental venous thromboembolism PW, B in cancer patients: prevalence and consequence. Thromb Res. 2010;125(6):e306-e309.

57. Dentali F, Ageno W, Becattini C, et al. Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis. Thromb Res. 2010;125(6):518-522. 58. Di Nisio M, Ferrante N, De Tursi M, et al. Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost. 2010;104(5): 1049-1054. 59. OConnell CL, Boswell WD, Duddalwar V, et al. Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol. 2006;24(30):4928-4932. 60. den Exter PL, Hooijer J, Dekkers OM, Huisman MV. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol. 2011;29(17):2405-2409. 61. Menapace LA, Peterson DR, Berry A, Sousou T, Khorana AA. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost. 2011;106(2):371-378. 62. OConnell CL, Razavi PA, Liebman HA. Symptoms adversely impact survival among patients with cancer and unsuspected pulmonary embolism. J Clin Oncol. 2011;29(31):4208-4209, author reply 4209-4210. 63. Sun JM, Kim TS, Lee J, et al. Unsuspected pulmonary emboli in lung cancer patients: the impact on survival and the significance of anticoagulation therapy. Lung Cancer. 2010;69(3):330-336. 64. Palareti G, Legnani C, Lee A, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost. 2000;84(5):805-810. 65. Carrier M, Khorana A, Zwicker J, Noble S, Lee A; The subcommittee on Haemostasis Malignancy for the SSC of the ISTH. Management of challenging cases of patients with cancerassociated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH [published online ahead of print June 27, 2013]. J Thromb Haemost. 66. Herishanu Y, Misgav M, Kirgner I, Ben-Tal O, Eldor A, Naparstek E. Enoxaparin can be used safely in patients with severe thrombocytopenia due to intensive chemotherapy regimens. Leuk Lymphoma. 2004;45(7):1407-1411. 67. Schiff D, DeAngelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer. 1994;73(2):493-498. 68. Olin JW, Young JR, Graor RA, Ruschhaupt WF, Beven EG, Bay JW. Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors. Anticoagulants or inferior vena cava filter? Arch Intern Med. 1987;147(12):2177-2179. 69. Choucair AK, Silver P, Levin VA. Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism. J Neurosurg. 1987;66(3): 357-358. 70. Altschuler E, Moosa H, Selker RG, Vertosick FT Jr. The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors. Neurosurgery. 1990;27(1):74-76, discussion 77. 71. Alvarado G, Noor R, Bassett R, et al. Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res. 2012;22(4):310-315. 72. Schmidt F, Faul C, Dichgans J, Weller M. Low molecular weight heparin for deep vein thrombosis in glioma patients. J Neurol. 2002; 249(10):1409-1412.

73. Vitale FV, Rotondo S, Sessa E, et al. Low molecular weight heparin administration in cancer patients with hypercoagulability-related complications and carrying brain metastases: a case series study. J Oncol Pharm Pract. 2012; 18(1):10-16. 74. Kovacs MJ, Kahn SR, Rodger M, et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost. 2007;5(8):1650-1653. 75. Drakos PE, Nagler A, Or R, Gillis S, Slavin S, Eldor A. Low molecular weight heparin for Hickman catheterinduced thrombosis in thrombocytopenic patients undergoing bone marrow transplantation. Cancer. 1992;70(7): 1895-1898. 76. Elman EE, Kahn SR. The post-thrombotic syndrome after upper extremity deep venous thrombosis in adults: a systematic review. Thromb Res. 2006;117(6):609-614. 77. Frank DA, Meuse J, Hirsch D, Ibrahim JG, van den Abbeele AD. The treatment and outcome of cancer patients with thromboses on central venous catheters. J Thromb Thrombolysis. 2000; 10(3):271-275. 78. Ogren M, Bergqvist D, Bjorck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol. 2006;12(13):2115-2119. 79. Thatipelli MR, McBane RD, Hodge DO, Wysokinski WE. Survival and recurrence in patients with splanchnic vein thromboses. Clin Gastroenterol Hepatol. 2010;8(2):200-205. 80. Ageno W, Riva N, Bang S, et al. Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry. In: Proceedings from the American Society of Hematology; December 8-11, 2012; Atlanta, GA. Abstract 499. 81. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012;119(13):3016-3023. 82. Bauersachs R, Berkowitz SD, Brenner B, et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510. 83. Buller HR, Prins MH, Lensin AW, et al; EINSTEINPE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14): 1287-1297. 84. Schulman S, Kearon C, Kakkar AK, et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24): 2342-2352. 85. Schulman S, Kearon C, Kakkar AK, et al; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709-718. 86. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. [published online ahead of print July 1, 2013]. N Engl J Med. 87. Agnelli G, Buller HR, Cohen A, et al; PLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013; 368(8):699-708. 88. Levine MN, Gu C, Liebman HA, et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost. 2012; 10(5):807-814.

Das könnte Ihnen auch gefallen